高级检索
当前位置: 首页 > 详情页

LINC00313 promotes the aggressiveness and tumorigenesis of cholangiocarcinoma through targeting miR-320b and MITF

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Kunming Univ Sci & Technol, Affiliated Hosp, Peoples Hosp Yunnan Prov 1, Dept Hepatobiliary & Pancreat Surg, 157 Jinbi Rd, Kunming 650100, Yunnan, Peoples R China
出处:
ISSN:

关键词: Cholangiocarcinoma LINC00313 miR-320b MITF Aggressiveness

摘要:
ObjectiveCholangiocarcinoma, a cancer of the biliary duct, is frequently diagnosed in advanced stages with poor prognosis. Understanding the molecular mechanisms driving its progression is crucial for developing effective treatment approaches. This research delves into the role of LINC00313 in regulating the aggressiveness of cholangiocarcinoma cells.MethodsClinical samples were collected to examine the expression pattern of LINC00313, miR-320b, and MITF using RT-qPCR and western blot analysis. Functional experiments, including cell proliferation, migration, and invasion assays, as well as apoptosis detection, were performed to assess the malignant properties of cholangiocarcinoma cells. The tumorigenic potential of cholangiocarcinoma cells was further investigated in a xenograft mouse model.ResultsElevated levels of LINC00313 were detected in both cholangiocarcinoma tumors and cell lines. Knocking down LINC00313 reduced the aggressiveness of cholangiocarcinoma cells and hindered their ability to form tumors in vivo. It was discovered that miR-320b is a target of LINC00313, exhibiting an expression pattern and functional role that contrasts with LINC00313. Moreover, the LINC00313/miR-320b axis was found to regulate the expression of MITF, thereby influencing the aggressiveness of cholangiocarcinoma cells.ConclusionLINC00313/miR-320b/MITF axis is implicated in the malignant progression of cholangiocarcinoma, indicating the potential of targeting LINC00313 as a strategy for cholangiocarcinoma clinical management.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 内分泌学与代谢 4 区 肿瘤学
JCR分区:
出版当年[2024]版:
Q2 ONCOLOGY Q3 ENDOCRINOLOGY & METABOLISM
最新[2024]版:
Q2 ONCOLOGY Q3 ENDOCRINOLOGY & METABOLISM

影响因子: 最新[2024版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2023版]

第一作者:
第一作者机构: [1]Kunming Univ Sci & Technol, Affiliated Hosp, Peoples Hosp Yunnan Prov 1, Dept Hepatobiliary & Pancreat Surg, 157 Jinbi Rd, Kunming 650100, Yunnan, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:92358 今日访问量:0 总访问量:782 更新日期:2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号 ICP备案:滇ICP备15003244号